Related Experiment Video
Updated: Sep 19, 2025
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Postprocedural Anticoagulation Following Primary Percutaneous Coronary Intervention for ST-Segment Elevation
Vinícius Martins Rodrigues Oliveira1, Natália Garcia Gaban2, Lucca Lopes3
1Department of Medicine, Federal University of Goiás, Goiânia, Goias, Brazil.
Insights
Postprocedural anticoagulation (PPAC) after percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) does not reduce mortality or major adverse cardiovascular events. However, PPAC increases the risk of major/minor bleeding.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Trials
Background:
- Procedural anticoagulation is standard in primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
- The necessity and efficacy of postprocedural anticoagulation (PPAC) following PCI in STEMI patients remain uncertain.
- This study evaluates the clinical impact of PPAC in STEMI management.
Purpose of the Study:
- To determine the effectiveness of PPAC in reducing mortality and adverse events post-PCI for STEMI.
- To assess the safety profile of PPAC, specifically focusing on bleeding risks.
- To provide evidence-based insights into current PPAC practices.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials and observational studies.
- Searched PubMed, Cochrane, and Embase databases for relevant literature.
- Statistical analyses performed using R 4.4.2 with a random-effects model to calculate risk ratios and confidence intervals.
Main Results:
- Analysis of five studies involving 47,310 patients revealed PPAC did not significantly decrease all-cause mortality, cardiac death, or major adverse cardiovascular events (MACE).
- Risks of stent thrombosis, myocardial infarction (MI), stroke, and TIMI major bleeding were comparable between PPAC and control groups.
- Patients receiving PPAC showed a significantly higher risk of TIMI major/minor bleeding and non-cardiac adverse events (NACE).
Conclusions:
- Postprocedural anticoagulation (PPAC) after PCI for STEMI offers no significant benefit in reducing mortality or major adverse cardiovascular events.
- PPAC is associated with an increased risk of major and minor bleeding events.
- Further randomized controlled trials are recommended to confirm these findings and guide clinical practice.
Background:
The use of procedural anticoagulation during primary percutaneous coronary intervention (PCI) is well established and has been shown to improve clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI). Despite its widespread application in clinical settings, the necessity and effectiveness of postprocedural anticoagulation (PPAC) remain contentious.
Aims:
To assess the effectiveness and safety of PPAC after PCI for the management of STEMI.
Methods:
We queried PubMed, Cochrane and Embase to identify studies comparing the clinical outcomes between control (placebo or no infusion) and PPAC after PCI for treating STEMI. The review was conducted using Cochrane and PRISMA guidelines, and R 4.4.2 was used to perform all statistical analyses. A random-effects model was employed to assess risk ratios (RRs) and their 95% confidence intervals (CIs).
Results:
A total of five studies comprising 47,310 patients were included, of which 32,548 (68.7%) received PPAC. Mean age ranged from 60.7 (12.4) to 70.0 (11.9) and 37,504 (79.2%) of them were female. Compared with control, PPAC did not significantly reduce all-cause mortality (RR 0.87; 95% CI 0.59-1.30; p = 0.61), cardiac death (RR 0.88; 95% CI 0.59-1.31; p = 0.52), and MACE (RR 1.03; 95% CI 0.75-1.41; p = 0.85). Moreover, the risk of stent thrombosis (RR 1.16; 95% CI 0.87-1.53; p = 0.31), MI (RR 1.02; 95% CI 0.78-1.32; p = 0.90), stroke (RR 0.97; 95% CI 0.36-2.57; p = 0.94) and TIMI major bleeding (RR 1.03; 95% CI 0.45-2.39; p = 0.94) were comparable across groups. However, patients assigned to PPAC were associated with higher risk of TIMI major/minor bleeding (RR 1.55; 95% CI 1.38-1.73; p < 0.01) and NACE (RR 1.36; 95% CI 1.14-1.61; p < 0.01).
Conclusions:
This meta-analysis reveals no significant differences in the risk of all-cause mortality, cardiac death, MACE, stent thrombosis, stroke and TIMI major bleeding between placebo and PPA after PCI in STEMI patients. However, PPAC is associated with higher risk of TIMI major/minor bleeding. Further randomized controlled trials are warranted to validate these findings.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:28Cardiac Catheterization I: Pre-Procedure Overview
01:30Acute Coronary Syndrome I: Introduction
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:27Peripheral Artery Disease III: Interprofessional Care